Developing Mouse Models Of Diffuse Large B Cell Lymphoma For Therapeutic Discovery
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
Diffuse large B cell lymphomas are aggressive cancers of white blood cells. Gene mutations play significant yet poorly understood roles in the cause of these lymphomas and their resistance to drug treatments. I plan to develop new mouse models of lymphoma to identify factors that cause lymphoma to develop in living organisms and factors that cause them to resist drug treatment. I will also test if combinations of multiple drugs can effectively and safely treat these lymphomas.
Targeting IAPs In Leukaemias Using The Smac-mimetic Drug Birinapant
Funder
National Health and Medical Research Council
Funding Amount
$969,304.00
Summary
Acute Myeloid Leukaemia (AML) is an aggressive blood cancer. Overall, less than 50% of AML patients are cured. This project evaluates a new drug, Birinapant, in the treatment of AML. Our research will define the AMLs that best respond to Birinapant, and discover combined therapies that will overcome drug resistance. Thus, this project will lead the way towards a clinical trial of Birinapant in AML, focusing on patients who benefit the most and treatments that increase numbers of who may respond.
Consequences Of MYD88 Mutations Commonly Found In Human B Cell Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$442,583.00
Summary
MYD88 is one of the most recurrently mutated genes in B cell malignancies, such as diffuse-large B cell lymphoma and Waldenström macroglobulinemia. This project will characterise oncogenic MYD88 mutations by introducing the mutations into normal mouse B cells. It will examine how the mutations disrupt signalling pathways and B cell functions and how the mutations respond to new lymphoma drugs. We hope this project will provide information for lymphoma pathogenesis and rational drug selection.
Epigenetic Regulation Of Self-renewal Signalling Pathway In Leukemic Stem Cell Formation
Funder
National Health and Medical Research Council
Funding Amount
$885,476.00
Summary
Acute myeloid leukaemia (AML) is a fatal form of blood cancer. The survival of patients with AML remains poor and this is due to the return of disease after chemotherapy (relapse). Leukemic stem cells (LSCs) are the major cause of relapse and we study how LSCs are regulated. This will provide valuable input into the development of novel therapeutic strategies to target therapy-resistant LSCs and improve AML outcome.
Studying The Novel Role For G Protein-coupled Receptor Signalling In Leukaemia Development
Funder
National Health and Medical Research Council
Funding Amount
$373,144.00
Summary
Recent research has shown the clinical importance of abnormal stem cells (LSC) in acute myeloid leukaemia (AML). LSC are resistant to therapeutics suggesting that they could be a cause of relapse. Identifying signalling pathways that drive LSC development is essential to selectively eradicate LSC that could offer substantial therapeutic benefit. This proposal aims to identify and evaluate critical signalling pathways as a potential therapeutic target for developing effective novel LSC-targeted t ....Recent research has shown the clinical importance of abnormal stem cells (LSC) in acute myeloid leukaemia (AML). LSC are resistant to therapeutics suggesting that they could be a cause of relapse. Identifying signalling pathways that drive LSC development is essential to selectively eradicate LSC that could offer substantial therapeutic benefit. This proposal aims to identify and evaluate critical signalling pathways as a potential therapeutic target for developing effective novel LSC-targeted therapy in AML.Read moreRead less
Individualising Tyrosine Kinase Inhibitor Therapy In CML To Facilitate Successful Treatment Free Remission
Funder
National Health and Medical Research Council
Funding Amount
$376,449.00
Summary
This project will determine the optimal therapy for patients with chronic myeloid leukaemia (CML), matching the most appropriate drug to the individual patient, based on each patient's unique biology, thereby maximising the chance of cure. Furthermore, this project will develop novel highly sensitive tests for the presence of residual disease, even if undetectable by current techniques. This will enable crucial, timely treatment changes to be made with curative intent.